Rajeka Lazarus

University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust

Bristol

United Kingdom

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 538

SSRN RANKINGS

Top 538

in Total Papers Downloads

66,933

SSRN CITATIONS

4

CROSSREF CITATIONS

2

Scholarly Papers (4)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Federal University of São Paulo (UNIFESP), University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand, Stellenbosch University - Family Centre for Research with Ubuntu, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, GSK plc, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, University of Liverpool - School of Tropical Medicine, University of Bristol - Bristol Vaccine Centre, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group and Independent
Downloads 52,364 (51)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge - Department of Medicine, University of Oxford - Big Data Institute, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, GSK plc, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Liverpool - School of Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Bristol - Bristol Vaccine Centre, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, Genomics England, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Independent and Independent
Downloads 11,012 (923)
Citation 26

Abstract:

Loading...

3.

The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV)

Number of pages: 36 Posted: 30 Sep 2021
University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, University Hospitals Bristol, Cardiff University - Centre for Trials Research, University of Bristol - Bristol Vaccine Centre, University Hospitals Bristol, Government of the United Kingdom - Royal United Hospitals Bath NHS Foundation Trust, Government of the United Kingdom - National Health Service (NHS), Government of the United Kingdom - Royal United Hospitals Bath NHS Foundation Trust, Public Health England - National Infection Service, University of Bristol, University of Bristol, University of Bristol, University of Bristol, National Health Service, United Kingdom, NIHR UCLH Clinical Research Facility, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University Hospitals Bristol - University Hospitals Bristol NHS Foundation Trust, Government of the United Kingdom - National Health Service (NHS), Government of the United Kingdom - National Health Service (NHS), Government of the United Kingdom - Great Western Hospitals, The Alverton Practice, University of Bristol, University of Bristol, University of Oxford - Centre for Vaccinology and Tropical Medicine, Government of the United Kingdom - National Health Service (NHS), Government of the United Kingdom - National Health Service (NHS), University of Nottingham - Division of Epidemiology and Public Health, University of Bristol - Bristol Vaccine Centre, University of Bristol and Independent
Downloads 3,357 (6,870)

Abstract:

Loading...

Concomitant vaccination, COVID-19 vaccine, Influenza vaccine, Clinical Trial

4.

Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator

Number of pages: 33 Posted: 01 Jun 2022
University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH and University of Bristol - Bristol Vaccine Centre
Downloads 200 (285,700)
Citation 1

Abstract:

Loading...

Coronavirus, SARS-CoV-2, COVID-19, whole-virus vaccine, inactivated vaccine, adjuvanted vaccine, neutralizing antibody, vaccine safety, S protein binding IgG antibody, RBD-binding IgG antibody, CpG 1018, aluminum hydroxide.